Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

Pickel, H; Petru, E; Lahousen, M; Stettner, H; Lehnert, M.
Efficacy of adjuvant carboplatin-epirubicin chemotherapy in advanced ovarian cancer after radical surgery.
Oncology. 1989; 46(4):222-225
Web of Science PubMed Google Scholar

 

Autor/innen der Med Uni Graz:
Lahousen Manfred
Petru Edgar
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
Postoperatively, 13 patients with stage III ovarian cancer received a combination of carboplatin and epirubicin (PE) at 300 and 60 mg/m2 respectively. The results of the 13 patients receiving the PE regimen were retrospectively compared to those of 24 patients who received the conventional PAC schedule (cisplatin, Adriamycin and cyclophosphamide at a dosage of 50, 50 and 750 mg/m2, respectively). All 37 patients had undergone radical debulking surgery including pelvic and paraaortic lymphadenectomy. At 8 months, relapse-free rates of 42.2 and 79.2% were observed in the PE and PAC groups, respectively. This difference was highly significant (p = 0.011). The data suggest that the PE combination has less antineoplastic activity than the PAC schedule and thus cannot be recommended in the adjuvant treatment of advanced ovarian cancer.
Find related publications in this database (using NLM MeSH Indexing)
Adult -
Aged -
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Carboplatin - adverse effects
Cisplatin - administration and dosage
Combined Modality Therapy - administration and dosage
Cyclophosphamide - administration and dosage
Doxorubicin - administration and dosage
Epirubicin - administration and dosage
Female - administration and dosage
Humans - administration and dosage
Middle Aged - administration and dosage
Organoplatinum Compounds - administration and dosage
Ovarian Neoplasms - drug therapy
Retrospective Studies - drug therapy

© Meduni Graz Impressum